RCC101: Treating advanced RCC

Once the initial renal cell carcinoma (RCC) starts to spread, it becomes advanced RCC.1,2

To treat advanced RCC, guidelines recommend a number of treatments belonging to one of two drug classes: Targeted therapies or immunotherapies.1,2

Treatments for advanced RCC

Drugs (generic name)
Targeted therapies Inlyta (axitinib)
Avastin (bevacizumab)
Cabometyx (cabozantinib)
Afinitor (everolimus)
Lenvima (lenvatinib)
Votrient (pazopanib)
Nexvar (sorafenib)
Sutent (sunitinib)
Torisel (temsirolimus)
Immunotherapies High-dose IL-2 Opdivo (nivolumab)
Combination therapies Avastin + interferon-α2a Lenvima + Afinitor

Generally, internationally recognized guidelines recommend:

  • Surgery to remove as much tumour tissue as possible.1,2
  • If RCC relapses or if not all tumours can be removed, start on an appropriate targeted therapy, combination therapy, or high-dose IL-2.1,2
  • Should the first-line treatment fail, options are to enroll in a clinical trial, or treat with another targeted therapy, immunotherapy, or combination therapy.1,2

Treatments are often chosen based on the patient’s risk of progression.

To learn more:

What to expect?

Managing side effects

References: 1. National Comprehensive Cancer Network. NCCN guidelines: Kidney cancer version 3.2016. Available at: https://www.nccn.org. Accessed on August 11, 2016. 2. Escudier B, et al. Ann Oncol 2014;25(Suppl 3):iii49-iii56.

Last updated: September 17, 2016.
Photo adapted from original by Jeremy Brooks, used under license.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s